Johnston, Jenessa N. http://orcid.org/0000-0003-2986-3179
Zarate, Carlos A. Jr. http://orcid.org/0000-0003-4442-7412
Kvarta, Mark D. http://orcid.org/0000-0002-1093-1648
Funding for this research was provided by:
National Institute of Mental Health
Article History
Received: 4 June 2024
Accepted: 3 July 2024
First Online: 13 July 2024
Declarations
:
: Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (<i>R</i>,<i> S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. Drs. Johnston and Kvarta have no conflict of interest to disclose, financial or otherwise.